PDCD1 and cancer: The two most well-characterized immune checkpoints targeted by ICIs are the CTLA-4,365,366 and the PD-1/PD-L1 pathways.367 These pathways play distinct but complementary roles in regulating immune responses, and their inhibition has led to significant clinical successes in treating various cancers.